Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,565 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer.
Tai Y, Chow A, Han S, Coker C, Ma W, Gu Y, Estrada Navarro V, Kandpal M, Hibshoosh H, Kalinsky K, Manova-Todorova K, Safonov A, Walsh EM, Robson M, Norton L, Baer R, Merghoub T, Biswas AK, Acharyya S. Tai Y, et al. Among authors: robson m. EMBO Mol Med. 2024 Aug;16(8):1957-1980. doi: 10.1038/s44321-024-00094-2. Epub 2024 Jul 2. EMBO Mol Med. 2024. PMID: 38956205 Free PMC article.
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Kauff ND, et al. Among authors: robson me. N Engl J Med. 2002 May 23;346(21):1609-15. doi: 10.1056/NEJMoa020119. Epub 2002 May 20. N Engl J Med. 2002. PMID: 12023992 Free article.
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC. Weigelt B, et al. Among authors: robson me. Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765325 Free PMC article.
Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma.
Hoda RS, Brogi E, Dos Anjos CH, Grabenstetter A, Ventura K, Patil S, Selenica P, Weigelt B, Reis-Filho JS, Traina T, Robson M, Norton L, Wen HY. Hoda RS, et al. Among authors: robson m. Mod Pathol. 2020 Nov;33(11):2221-2232. doi: 10.1038/s41379-020-0606-0. Epub 2020 Jul 1. Mod Pathol. 2020. PMID: 32612248 Free PMC article.
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.
Ferraro E, Singh J, Patil S, Razavi P, Modi S, Chandarlapaty S, Barrio AV, Malani R, Mellinghoff IK, Boire A, Wen HY, Brogi E, Seidman AD, Norton L, Robson ME, Dang CT. Ferraro E, et al. NPJ Breast Cancer. 2022 Mar 22;8(1):37. doi: 10.1038/s41523-022-00380-7. NPJ Breast Cancer. 2022. PMID: 35319017 Free PMC article.
1,565 results